SCHEDULE: Opaleye Management Reports 6.14% Stake in Pasithea Therapeutics

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 2,050,000 shares of Pasithea Therapeutics Corp. common stock, representing 6.14% of the outstanding shares.

Summary

• Opaleye Management Inc., Opaleye L.P., and James Silverman (collectively, the Reporting Persons) have filed an amendment to their Schedule 13G filing.
• The filing indicates that the Reporting Persons beneficially own 2,050,000 shares of Pasithea Therapeutics Corp. common stock.
• This ownership stake represents 6.14% of the company's outstanding common stock.
• The shares are directly held by Opaleye, L.P., with Opaleye Management Inc. acting as the investment adviser and James Silverman as the controlling person of the Adviser.
• The filing clarifies that this statement does not constitute an admission of beneficial ownership for purposes of Section 13 of the Securities Exchange Act of 1934, as amended.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of a significant ownership stake, providing transparency without offering new operational or financial performance data.

Positives

• Significant ownership stake of 6.14% reported by a notable investment entity.
• Clear disclosure of beneficial ownership and reporting structure.

Negatives

• The filing does not contain any negative financial or operational information as it is a Schedule 13G disclosure of ownership.

Risks

• The filing does not explicitly mention any risks. However, any significant ownership stake can imply potential for future activism or influence on corporate strategy, which could be perceived as a risk by existing management or other shareholders.

Future Outlook

The filing is a Schedule 13G, which reports ownership stakes and does not contain forward-looking statements or guidance from the company itself.

Management Comments

• The filing of this statement shall not be construed as an admission that any Reporting Person is the beneficial owner of any securities covered by this statement for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or otherwise.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates a notable investment by Opaleye Management in Pasithea Therapeutics, which could signal confidence in the company's prospects or a strategy to influence corporate actions.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure, which is a regulatory requirement for entities beneficially owning more than 5% of a class of a company's registered equity securities. The reporting format and content align with industry norms for such filings.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant shareholder's stake, potentially influencing market perception and trading activity.
• Management: May face increased scrutiny or engagement from a substantial institutional investor.
• Potential Investors: Provides information on the ownership structure and key stakeholders.

Next Steps

• The Reporting Persons may continue to monitor Pasithea Therapeutics' performance and strategy.
• Further amendments to the Schedule 13G may be filed if beneficial ownership changes significantly.

Key Dates

Keywords

Pasithea Therapeutics, Opaleye Management, Opaleye L.P., James Silverman, Schedule 13G, Beneficial Ownership, Investment Adviser, Shareholder